A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2018
At a glance
- Drugs GRF-6019 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Alkahest
- 29 Oct 2018 According Alkahest media release, data from this trial was presented at the Clinical Trials in Alzheimer's Disease (CTAD) Conference in Barcelona on 26th October.
- 26 Jul 2018 Trial design presented at the Alzheimer's Association International Conference 2018
- 23 Jul 2018 According Alkahest media release, data from this syudy will be preasented at Alzheimers Association International Conference (AAIC) Annual Meeting.